Spears Abacus Advisors Cut By $2.01 Million Its Thermo Fisher Scientific (TMO) Stake; Magellan Health Services Has 0.98 Sentiment

December 20, 2017 - By Nellie Frank

Magellan Health, Inc. engages in the healthcare management business in the United States. The company has market cap of $2.38 billion. The companyÂ’s Healthcare segment engages in the management of behavioral healthcare services and employee assistance program services; management of other specialty areas, including diagnostic imaging and musculoskeletal management; and the integrated management of physical, behavioral, and pharmaceutical healthcare for special populations comprising individuals with serious mental illness, dual eligibles, long-term services and supports, and other populations with unique and often complex healthcare needs. It has a 26.26 P/E ratio. This segment provides its healthcare services through its comprehensive network of medical and behavioral health professionals, clinics, hospitals, and ancillary service providers.

Spears Abacus Advisors Llc decreased Thermo Fisher Scientific Inc (TMO) stake by 5.81% reported in 2017Q2 SEC filing. Spears Abacus Advisors Llc sold 11,566 shares as Thermo Fisher Scientific Inc (TMO)’s stock rose 8.13%. The Spears Abacus Advisors Llc holds 187,362 shares with $32.69M value, down from 198,928 last quarter. Thermo Fisher Scientific Inc now has $76.81B valuation. The stock decreased 1.21% or $2.35 during the last trading session, reaching $191.54. About 500,138 shares traded. Thermo Fisher Scientific Inc. (NYSE:TMO) has risen 15.57% since December 20, 2016 and is uptrending. It has underperformed by 1.13% the S&P500.

Since January 1, 0001, it had 0 insider buys, and 16 selling transactions for $17.85 million activity.

The stock increased 0.30% or $0.3 during the last trading session, reaching $99.2. About 10,912 shares traded. Magellan Health, Inc. (MGLN) has risen 5.31% since December 20, 2016 and is uptrending. It has underperformed by 11.39% the S&P500.

Altalis Capital Management Llc holds 5.06% of its portfolio in Magellan Health, Inc. for 91,207 shares. Dean Capital Management owns 60,949 shares or 2.14% of their US portfolio. Moreover, Hood River Capital Management Llc has 1.75% invested in the company for 348,245 shares. The Texas-based Smith Graham & Co. Investment Advisors Lp has invested 1.21% in the stock. Dean Investment Associates Llc, a Ohio-based fund reported 94,325 shares.

Analysts await Magellan Health, Inc. (NASDAQ:MGLN) to report earnings on February, 23. They expect $2.09 earnings per share, up 25.15% or $0.42 from last year’s $1.67 per share. MGLN’s profit will be $50.21M for 11.87 P/E if the $2.09 EPS becomes a reality. After $1.52 actual earnings per share reported by Magellan Health, Inc. for the previous quarter, Wall Street now forecasts 37.50% EPS growth.

Analysts await Thermo Fisher Scientific Inc. (NYSE:TMO) to report earnings on January, 30. They expect $2.67 EPS, up 10.79% or $0.26 from last year’s $2.41 per share. TMO’s profit will be $1.07 billion for 17.93 P/E if the $2.67 EPS becomes a reality. After $2.31 actual EPS reported by Thermo Fisher Scientific Inc. for the previous quarter, Wall Street now forecasts 15.58% EPS growth.

Among 17 analysts covering Thermo Fisher Scientific (NYSE:TMO), 16 have Buy rating, 0 Sell and 1 Hold. Therefore 94% are positive. Thermo Fisher Scientific had 51 analyst reports since July 24, 2015 according to SRatingsIntel. As per Wednesday, October 11, the company rating was maintained by Cowen & Co. Robert W. Baird maintained the shares of TMO in report on Monday, October 2 with “Buy” rating. Goldman Sachs upgraded the shares of TMO in report on Tuesday, December 8 to “Americas Conviction Buy List” rating. The rating was initiated by Argus Research on Tuesday, October 6 with “Buy”. The stock of Thermo Fisher Scientific Inc. (NYSE:TMO) earned “Overweight” rating by JP Morgan on Thursday, September 22. Jefferies maintained it with “Hold” rating and $195.0 target in Tuesday, August 22 report. The company was maintained on Monday, September 25 by Barclays Capital. As per Tuesday, July 19, the company rating was maintained by Barclays Capital. The firm earned “Buy” rating on Tuesday, September 26 by Goldman Sachs. BTIG Research reinitiated the shares of TMO in report on Friday, July 22 with “Buy” rating.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: